MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Arcadia Biosciences, Inc. (RKDA)

Arcadia Biosciences, Inc. (RKDA)

|||

Balance Sheets Overview

Current Ratio
348.66%
Quick Ratio
292.16%
Cash Ratio
253.83%
Debt to Asset Ratio
89.26%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Accounts receivable and other re...
    • Other noncurrent assets
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Common stock warrant and option ...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
4,178
954
259
1,120
Short-term investments
0
2,766
4,304
4,765
Accounts receivable and other receivables, net of allowance for credit loss of 559 as of june 30, 2026 and december 31, 2025
559
425
425
831
Inventories
930
840
1,212
1,457
Note receivable - current, net of allowance for credit losses (note 8)
-
-
0
0
Prepaid expenses and other current assets
72
184
156
214
Current assets of discontinued operations - goodwheat
-
-
0
0
Total current assets
5,739
5,169
6,356
8,387
Property and equipment, gross
-
-
1,907
-
Less accumulated depreciation and amortization
-
-
1,899
-
Property and equipment, net
0
0
8
10
Right of use assets
-
-
0
0
Intangible assets, net
39
39
39
39
Note receivable - noncurrent, net of allowance for credit losses (note 8)
-
-
0
0
Other noncurrent assets
115
115
143
148
Total assets
5,893
5,323
6,546
8,584
Accounts payable and accrued expenses
1,383
1,102
1,789
2,015
Other current liabilities-Related Party
-
-
0
0
Operating lease liability - current
-
-
0
0
Other current liabilities
263
263
270
270
Total current liabilities
1,646
1,365
2,059
2,285
Common stock warrant and option liabilities
3,614
1,073
347
856
Other noncurrent liabilities
-
-
0
0
Total liabilities
5,260
2,438
2,406
3,141
Common stock, 0.001 par value - 150,000,000 shares authorized as of june 30, 2026 and december 31, 2025 2,181,715 and 1,373,120 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
66
66
65
65
Additional paid-in capital
292,435
288,421
285,292
285,259
Accumulated deficit
-291,868
-285,602
-281,217
-279,881
Total stockholders' equity
633
2,885
4,140
5,443
Total liabilities and stockholders equity
5,893
5,323
6,546
8,584
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$4,178K (203.63%↑ Y/Y)Inventories$930K (-37.54%↓ Y/Y)Accounts receivable andother receivables,...$559K (-55.78%↓ Y/Y)Prepaid expenses andother current assets$72K (-81.20%↓ Y/Y)Total current assets$5,739K (-24.28%↓ Y/Y)Other noncurrentassets$115K (-22.30%↓ Y/Y)Intangible assets, net$39K (0.00%↑ Y/Y)Total assets$5,893K (-24.33%↓ Y/Y)Total liabilities andstockholders equity$5,893K (-24.33%↓ Y/Y)Total liabilities$5,260K (61.60%↑ Y/Y)Total stockholders'equity$633K (-86.04%↓ Y/Y)Accumulated deficit-$291,868K Common stock warrantand option...$3,614K (155.23%↑ Y/Y)Total currentliabilities$1,646K (-10.49%↓ Y/Y)Additional paid-in capital$292,435K Common stock, 0.001 parvalue - 150,000,000...$66K Accounts payable andaccrued expenses$1,383K (-11.23%↓ Y/Y)Other currentliabilities$263K (-2.59%↓ Y/Y)